End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.73 EUR | -2.67% | -9.32% | -12.05% |
2021 | Aap Implantate AG Announces Sales Results for the Second Quarter and Half Year Ended 30 June 2021 | CI |
2021 | Aap Implantate Ag Reports Earnings Results for the Full Year Ended December 31, 2020 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.05% | 12.23M | - | ||
-3.32% | 184B | C+ | ||
-2.21% | 107B | C | ||
-4.18% | 67.78B | A | ||
+0.86% | 50.66B | B- | ||
+10.59% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+1.07% | 26.3B | B | ||
+1.22% | 26.04B | A- | ||
+15.06% | 25.4B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AAQ1 Stock
- AAQ Stock
- Ratings aap Implantate AG